Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
Memorial Sloan Kettering Cancer Center · Cornell University · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
586
total citations
- FWCI
- 82.00
- Percentile
- 100%
- References
- 20
Citations per year
Authors
19- WDWilliam D. TapCorresponding
Memorial Sloan Kettering Cancer Center, Cornell University
- RLRobin L. Jones
Royal Marsden Hospital, Seattle University
- BABrian A. Van Tine
Washington University in St. Louis
- BCBartosz Chmielowski
UCLA Medical Center, UCLA Jonsson Comprehensive Cancer Center
- AEAnthony Elias
University of Colorado Denver, University of Colorado Cancer Center
Topics & keywords
Topics
Keywords
- Doxorubicin
- Soft tissue sarcoma
- Medicine
- Open label
- Oncology
- Sarcoma
- Internal medicine
- Phase (matter)
UN Sustainable Development Goals
- No poverty
No related works found for this paper.